Terms: = Prostate cancer AND PAX5, Q02548, 5079, ENSG00000196092, BSAP AND Diagnosis
9 results:
1. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Noé V; Aubets E; Félix AJ; Ciudad CJ
Biochem Pharmacol; 2021 Jul; 189():114371. PubMed ID: 33338475
[TBL] [Abstract] [Full Text] [Related]
2. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
3. A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan.
Wu CC; Lin CH; Chiang HS; Tang MJ
Int J Equity Health; 2018 Jun; 17(1):79. PubMed ID: 29903010
[TBL] [Abstract] [Full Text] [Related]
4. Poor Follow-up After Elevated prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract] [Full Text] [Related]
5. prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer.
Paoluzzi M; Losa A; Cerboneschi V; Colosimo C; Fontana N; Mangili P; Mignogna M; Nava L; Ravaglia V
Brachytherapy; 2017; 16(5):1000-1006. PubMed ID: 28642046
[TBL] [Abstract] [Full Text] [Related]
6. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant prostate cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic and prognostic use of bone turnover markers.
Joerger M; Huober J
Recent Results Cancer Res; 2012; 192():197-223. PubMed ID: 22307377
[TBL] [Abstract] [Full Text] [Related]
8. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
[TBL] [Abstract] [Full Text] [Related]
9. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract] [Full Text] [Related]
